Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Teijin Pharma, the core company of Japan’s Teijin Group’s healthcare business, says that its board of directors has elected Akihisa Nabeshima as its next president. 22 February 2017
While last week’s news continued to be dominated by actions of newly-installed US President Donald Trump, including the vote to approve his controversial nominee Dr Tom Price as Secretary of Health and Human Services, the pharma industry itself was also making headlines. 12 February 2017
Oxford BioTherapeutics (OBT) has added two new names to a board now boasting significant experience in developing immuno-oncology and antibody-based therapies. 9 February 2017
Erez Vigodman is stepping down from his post as chief executive of Teva Pharmaceutical Industries “by mutual agreement,” the Israeli generics giant announced late Monday. 7 February 2017
Thomas Cueni has taken up office as director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on February 1, representing the interests of the research-based biopharmaceutical industry at a global level. 7 February 2017
Sanofi today announces the appointment of Hugo Fry as general manager for the UK and general manager Sanofi Pasteur for the UK & Ireland, and Dr Hubert Bland as UK medical chair and medical head of diabetes and cardiovascular for the UK & Ireland. 1 February 2017
French pharma major Sanofi today announced the appointment of Kathleen Tregoning as a new member of the executive committee, effective February 27, 2017. 30 January 2017
US biotech firm Juno Therapeutics has appointed Corsee Sanders as executive vice president and head of development operations, effective immediately. 29 January 2017
On January 26, 2017, Dr Arie Belldegrun resigned as a member of the board of directors of Teva Pharmaceutical Industries, according to a company regulatory filing. 27 January 2017
EMD Serono, the biopharmaceutical business of German pharma major Merck KGaA in the USA and Canada, has announced that Richard Smith has been appointed its head of US fertility and endocrinology. 25 January 2017
Monoclonal antibody specialist Kymab has appointed Arndt Schottelius as its first executive vice president of research and development (R&D). 23 January 2017
A major change at the top of GlaxoSmithKline’s pharmaceutical business has been announced as part of what has been described as ‘succession processes’ at the company. 19 January 2017